Member Info for B2HS2L

For those who don't have this:
Preamble
David: What attracted me to the company is that the company had the key ingredients for future value creation.
I saw a solid number of building blocks, strong talents, a strong product portfolio, already established R&D and manufacturing supply chain, a commercial organisation with international reach, and accrued cash on balance in the bank, so essential building blocks which are hard to come by in any business.
I think I'm of the DNA to really make a difference in the company, take it to the next level and leave a legacy beyond that which the company has already achieved.

Last but not least, the other reason I joined was I felt comfortable at home with the team, a sense of belonging but a really talented team of individuals.

2.04 Katie:
Since joining in October last year, you have undertaken a strategic review of the business.
Tell us more about your key findings and the conclusions you made and how they support your view of the future direction of the business.

David: Yeah, so I have taken some time to really dig in and listen and learn about the company, and it's very clear to me that the companies great strength has been its ability to be agile and react quickly in the face of infectious disease previously reacting to outbreaks of Zika, Ebola, H1N1 swine flu, but actually Covid-19, - the first company in Europe to produce a CE mark in-vitro diagnostic test.
I guess the first thing is I really appreciated the strengths of the company and when one is thinking about strategy leveraging strength is the best start point.
It is of no surprise to any of us that in the infectious disease space that the risks are increasing.
We've seen that with the pandemic, with viruses, the ongoing problems with antimicrobial resistance. As we overuse antibiotics the understated problems we see with fungal infections, under appreciated or untreated and with climate change of course, diseases are moving with their ****that carry them around the world. So there is a whole list of reasons why infectious diseases are becoming even more problematic in a sense a resurgence perhaps of the past.
The way I have tried to think about the unmet needs the challenges and leveraging the strength of the company is to be much clearer for the company going forward with its vision, so we really want to hone that and become a leading global clinical diagnostic in the fight against infectious disease.
WE'VE done that before and we will do more in that regard.
With our purpose being to protect people by providing the right information at the right place at the right time, actionable health information, and protecting people from the invisible threat.

Evening Poidster -
This was a takeaway portion from the 25.01.2022 Proactive investor interview with DA.:

"..Then we really want to, with our new commercial relations, build on that market led or customer led strategy going forwards to identify areas of unmet needs, that we can deploy our resources towards solutions for customers, where they have gaps now, in the context of infectious disease.
So what you will see are two things, one is the R&D team - with the commercial team - will pick which opportunities to go after in the future.
That’s in the organic piece of the investment going forward, and increasingly we are looking at enhancing our business development efforts to bolster the portfolio and really remain agile, the companies always been agile."

I am expecting DA to say decisions have been made concerning infectious disease, - I'm not sure he will say exactly what areas we will be addressing, since he (and GM) has a history of not being explicit.
He sounds like he wants to be specific, - lets see what we get.

Here's my post from 12th April -
"NCYT shareholders are never going to experience true value, unless the company adopts less secretive ways of announcing deals with the likes of TATA MD and any other 'partnerships'.

From 25.01.2022 Strategy and Full Year 2021 Trading Update RNS

"In the interim, Novacyt continues to build a strong pipeline of business development opportunities for partnership, licensing, and M&A to strengthen the business and accelerate growth."

Also private testing labs.

IMO, officially, shareholders aren't aware of half of what has been going on, and until that knowledge is in the public domain, we will not realise full value."

++++

IMO nothing would work better for shareholder value creation than jointly developing a request for information for the 28th, and each individually sending THE SAME post to Mandy AND the INVESTOR MEET COMPANY platform.
That way we will know subsequently if our info request has been deliberately ignored.
Now that main members of BoD / some directors are on the same hymn sheet with respect to skin in the game, (and the unfathomable depth of the swamp the share price fall has dragged some shareholders into), we should list as many subjects that require answers as possible, then develop a simple information request consisting of a list.

I am aware the RNS states "The webinar is open to all existing and potential investors and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform."
I'll take a guess that this presentation is what they want investor questions on.
As there are few opportunities each year for investors to query the board, we should be taking every opportunity to try to maximise shareholder value by requesting answers to questions the board would rather avoid.

I'll start the list with this issue:

1 What information can be provided on the deal between IT-IS International instruments and TATA MD in India?
Nothing is not an option.
++++
To encourage more participation by fellow posters, please add your query to the above, and we can send THE SAME TEXT when all have had an opportunity to post.

Not interested in 'the company can't tell us that - its probably confidential', let David decide that.
AFAIK the only subject that applies to is the DHSC dispute, everything else is fair game.

I am sick of the continued undervaluation of this share price, with no end in sight. I want us all to be owners of shares that are much closer to true value, so when we sell we sell nearer to full valuation.

Chas PB - Too easy for them to ignore.

"It is interesting who they have left out - just the CFO and CEO involved. Hopefully, this will be numbers driven but still include some details on product innovation."

I am hoping this does not limit the type of investor questions the CEO and CFO can answer, as some questions are taken from the investor queries arriving on the day.

From the Admissions document (page 17) 18.10.2017:
https://novacyt.com/wp-content/uploads/2017/10/Admission-Document-Novacyt-18-October-2017.pdf

It is lab21 that has the links to large B2B partnerships.

"Lab21’s primary growth focus is the launch of complementary products into current markets as
well as adding new territories such as Brazil and the US. A significant portion of the Lab21
business has historically been tender driven from NGOs, for developing markets, an area that is
currently seeing significant recovery. In addition, Lab21 has a successful history of developing
major B2B partnerships with companies such as Becton, Dickinson and Company, Beckman
Coulter, The Danaher Corporation, Bio-Rad Laboratories, Inc. and will continue to focus on
developing such relationships to the benefit of the Group as a whole."

https://www.thehindu.com/business/tata-digital-to-acquire-majority-stake-in-1mg/article34785024.ece
Source The Hindu:
June 11 2021
Tata Digital to acquire majority stake in 1MG

Tata Digital Ltd., a 100% subsidiary of Tata Sons, has entered into an agreement to acquire majority stake in 1MG Technologies Pvt. Ltd., a digital health company, for an unspecified amount.

1MG enables easy & affordable access to medicines, health and wellness products, diagnostics services & tele-consultation to customers.

The company operates 3 diagnostics labs, has a supply chain covering over 20,000 pincodes across the country.

Through its subsidiaries it is also engaged in the business of B2B distribution of medicines & other healthcare products.

The investment is in line with Tata Group’s vision of creating a digital ecosystem which addresses the consumer needs across categories in a unified manner, the company said.

“The investment strengthens Tata’s ability to provide superior customer experience and high quality healthcare products & services in e-pharmacy and e-diagnostics space through a technology led platform,” said Pratik Pal, CEO, Tata Digital.

“This marks a significant milestone in our journey to make high quality healthcare products & services accessible to customers across India,” said Prashant Tandon, co-founder & CEO, 1MG.

+++

Thanks to Saintsmith / Kaeren for digging.

Docdaneeka -
"They're hoping for dramatic A2 news (which must be unlikely given the A2 protocol - but must also be a possibilty as NIH are still looking at it ! "

NIH are green lighting progression to A3, - and that study design is not settled.
What has been unsettling is the duff Sprinter phase 3 trial results, but nobody in NIH is going to finalise phase 3 study design until the deep dive findings, which may have useful findings for A3, to be announced on 13 May.

Page 17
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1067672/Technical-Briefing-40-8April2022.pdf

Page 20
XE mentioned

Appeal process and SOME timescales:
https://www.gov.uk/government/publications/planning-appeals-dealt-with-by-written-representations-taking-part/guide-to-taking-part-in-planning-and-listed-building-consent-appeals-proceeding-by-written-representations-england

Yes HarChris.
I was looking at how the revenue had been achieved in terms of margins.
If much of Biosynex's products are sold retail in chemists, I can see why their margins are lower.
Our turnover seems best when need for our products is highest, and the rest of the time we don't sell as well because gross margin has not been reduced, regardless of demand.
Source 2018-21 RNS's

I hope you are correct HarChris, and we have indeed had a good first quarter.
Biosynex have achieved a margin of 50% recently.
We have historically operated on a 60-70% margin.

EXMEX -
This web page states 2014:
https://www.labmedica.com/?option=asearch&search=primerdesign

BYP -
NCYT shareholders are never going to experience true value, unless the company adopts less secretive ways of announcing deals with the likes of TATA MD and any other 'partnerships'.

From 25.01.2022 Strategy and Full Year 2021 Trading Update RNS

"In the interim, Novacyt continues to build a strong pipeline of business development opportunities for partnership, licensing, and M&A to strengthen the business and accelerate growth."
also from same RNS
"The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates."

Also private testing labs.

IMO, officially, shareholders aren't aware of half of what has been going on, and until that knowledge is in the public domain, we will not realise full value.

Rifleman what normaly happend when a new VOC variant is announced?
Correct, - R&D busy on new SNPsig product.
Nothing happening here...

If you haven't checked in for a while, do you know of TATA MD selling instruments in India?
You might not know that management have completely avoided providing news on this subject.
"First time I’ve checked in here in 3 months ", yet it's OK to rubbish the company?
Always room for more researchers Rifleman

fali41 -
Two new VoC reported and 'market is not interested in anything covid related any longer'
Boris 'not going to take any option off the table' if a new deadly variant arises.
Why does the PM mention that if there is no threat?

Why so?

'Long Covid' last mentioned in 11.11.2021 RNS -

"Synairgen will continue to work on the SPRINTER study with Parexel Biotech, a division of the leading global clinical research organisation, Parexel. Day 35 data will be reported in the first instance followed by the long COVID results which will be collected until Day 90."

"talk of replacing the CEO with a Polygon friendly CEO." - 10.22 today -
IMO it is most likely that Polygon won't try to depose the CEO.
A candidate CEO might be put up by the purchaser of Polygons shares.
The mechanism to do that is here.

Companies Act Section 303 - calling general meetings by those entities owning more than 5% of the company:
https://www.legislation.gov.uk/ukpga/2006/46/section/303

Powerful shareholders have ousted CEO's using this rule in the past.

Lebus -
I had in mind that big pharma were looking to Polygon to find > 27% to add to their accumulated < 3%.
Hopefully there is more than one large pharma like this!
Deep dive data and Activ-2 data when released, and any Active phase 3 trial agreement should concentrate a few minds concerning the status of SNG001.